Clinical trial KESTREL
A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
| Cancers | |
|---|---|
| Organ | Head and Neck |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2015-003589-10 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02551159 |
| Inclusion criteria | First line of immune-mediated therapy. Fresh tumor biopsy |
| Last update |